🔗 Visit the ClinicalTrials.gov page for NCT01955499
| Rank | Title | Journal | Year | PubWeight™‹?› |
|---|---|---|---|---|
| 1 | Novel Targeted Agents in Hodgkin and Non-Hodgkin Lymphoma Therapy. | Pharmaceuticals (Basel) | 2015 | 0.78 |
| 2 | B-cell receptor pathway modulators in NHL. | Hematology Am Soc Hematol Educ Program | 2015 | 0.76 |
| 3 | Excellent Outcome of Immunomodulation or Bruton's Tyrosine Kinase Inhibition in Highly Refractory Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type. | Rare Tumors | 2015 | 0.75 |